The Drug Development Letter

The Drug Development Letter

Home
Archive
About
The 19th St Gallen Breast Oncology Conference begins on 12 March 2025 : "Should we combine adjuvant drugs that were tested in isolation in…
Our paper with Vinay Prasad is now published in the Journal of Cancer Policy – and it couldn’t be more timely!
 • 
Timothée Olivier
1
The ‘Duck Test’ for Huey, Dewey and Louie: the legal case on CDK4/6 inhibitors
Me-too drugs (drugs with the same mode of action for the same indication) are generally beneficial to society as they provide variation, choice and…
 • 
Sahar van Waalwijk
 and 
Hans Westgeest
CDK4/6 Inhibitors and Novel Adjuvant Therapies: Using Statistics to Inform Shared Decision-Making
Here is the talk I gave on March 3rd 2025 at the CRUK Cambridge Institute. Thanks again to Dr. Henno Martin and the team for the invitation and the…
 • 
Timothée Olivier
5
1:01:48

February 2025

Vaccine Safety Research: Too Much Confounding and Spin.
In a systematic review, we found that authors of vaccine safety observational studies conceded residual confounding in about 75% of the studies…
 • 
Mariana B. Caiado Ferreira
1
The CABINET study
100% NIH funded; 100% placebo controlled
 • 
Vinay Prasad
3
19:17
Excessive Drug Price Leads to Hefty Fine for Company in the Netherlands
Why was a company fined €17 million for excessive pricing?
 • 
Sahar van Waalwijk
1
Did pembrolizumab improve survival in patients with locally advanced cervical cancer due to poor access to post-protocol care?
We recently published our analysis in the journal Cancer, explaining why we believe an trial testing pembrolizumab in this setting – KEYNOTE-A18 …
 • 
Bart Penninx
, 
Michael Samson
, and 
John-John Schnog
4
Home-Grown CAR-T Cells: A Blessing or a Threat?
Biotech's pushback against the development of academic CAR-T cell therapy in the Netherlands.
 • 
Sahar van Waalwijk
1

January 2025

"The landscape of checkpoint inhibitors in oncology" – part 2! Expanding Approvals, Eligibility, and Response
How many patients are eligible for and respond to checkpoint inhibitors? Here is our eagerly awaited updated analysis, now also including the regulatory…
 • 
Alyson Haslam
1
One Arena Where You Can Bend the Rules to Your Advantage: Clinical Trials
Why changing the primary endpoint "target" of a trial is considered a questionable research practice.
 • 
Sahar van Waalwijk
Does the clinical value of a drug predict Medicare expenditures?
In short, the answer is negative, as we found in our study published in the Journal of Cancer Policy. Our analysis also revealed other interesting…
 • 
Ashley Nee
5

December 2024

© 2025 Vinay Prasad
Privacy ∙ Terms ∙ Collection notice
Start WritingGet the app
Substack is the home for great culture